Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 78

Results For "RSE"

2076 News Found

Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases
News | June 10, 2025

Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases

Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,


Fujifilm rebrands life sciences companies to strengthen position as strategic partners for life
News | June 07, 2025

Fujifilm rebrands life sciences companies to strengthen position as strategic partners for life

Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life


Thyrocare opens diagnostic lab in Srinagar
News | June 06, 2025

Thyrocare opens diagnostic lab in Srinagar

33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley


Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy
News | June 06, 2025

Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)


Arvinas and Pfizer's Vepdegestrant significantly improves progression-free survival for patients with ESR1-Mutant, ER+/HER2- advanced breast cancer
Clinical Trials | June 02, 2025

Arvinas and Pfizer's Vepdegestrant significantly improves progression-free survival for patients with ESR1-Mutant, ER+/HER2- advanced breast cancer

Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer


Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
News | June 02, 2025

Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio


Pfizer’s Braftovi combination regime reduces death risk  for patients with  BRAF V600E mutant mCRC
Clinical Trials | May 31, 2025

Pfizer’s Braftovi combination regime reduces death risk for patients with BRAF V600E mutant mCRC

Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment


Pimicotinib demonstrates best-in-class potential with significant efficacy and clinically meaningful improvements in patients with tenosynovial giant cell tumor
News | May 29, 2025

Pimicotinib demonstrates best-in-class potential with significant efficacy and clinically meaningful improvements in patients with tenosynovial giant cell tumor

MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume


Venus Remedies joins United Nations Global Compact
Sustainability | May 21, 2025

Venus Remedies joins United Nations Global Compact

This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery